Staphylococcus aureus - Antimicrobial resistance and the immunocompromised child

Infection and Drug Resistance

Volumn 7, Issue , 2014, Pages 117-127

  McNeil, J Chase ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; HIV; Pediatric; Transplant

Indexed keywords

BETA LACTAM ANTIBIOTIC; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; LINEZOLID; VANCOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL COLONIZATION; BLOODSTREAM INFECTION; CD4+ T LYMPHOCYTE; CHRONIC GRANULOMATOUS DISEASE; EMPYEMA; FEBRILE NEUTROPENIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPER IGE SYNDROME; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE ADHESION DEFICIENCY; MALIGNANT NEOPLASTIC DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NONHUMAN; ORGAN TRANSPLANTATION; PHENOTYPE; PNEUMONIA; PULSED FIELD GEL ELECTROPHORESIS; REVIEW; RISK FACTOR; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SURGICAL INFECTION; TH17 CELL; VIRUS LOAD;

EID: 84900416861     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/IDR.S39639     Document Type: Review

References (111)

1. Moran GJ, Krishnadasan A, Gorwitz RJ, et al; EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7): 666-674.
2. Gonzalez BE, Teruya J, Mahoney DH Jr, et al. Venous thrombosis associated with staphylococcal osteomyelitis in children. Pediatrics. 2006;117(5):1673-1679.
3. Gonzalez BE, Hulten KG, Dishop MK, et al. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin Infect Dis. 2005;41(5):583-590.
4. Martínez-Aguilar G, Avalos-Mishaan A, Hulten K, Hammerman W, Mason EO Jr, Kaplan SL. Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J. 2004;23(8):701-706.
5. Pannaraj PS, Hulten KG, Gonzalez BE, Mason EO Jr, Kaplan SL. Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2006;43(8):953-960.
6. McKinnell JA, Miller LG, Eells SJ, Cui E, Huang SS. A systematic literature review and meta-analysis of factors associated with methicillin-resistant Staphylococcus aureus colonization at time of hospital or intensive care unit admission. Infect Control Hosp Epidemiol. 2013;34(10):1077-1086.
7. Dukic VM, Lauderdale DS, Wilder J, Daum RS, David MZ. Epidemics of community-associated methicillin-resistant Staphylococcus aureus in the United States: a meta-analysis. PLoS One. 2013;8(1):e52722.
8. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003;290(22):2976-2984.
9. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA. 1998;279(8):593-598.
10. David MZ, Glikman D, Crawford SE, et al. What is community-associated methicillin-resistant Staphylococcus aureus? J Infect Dis. 2008;197(9):1235-1243.
11. Liu C, Graber CJ, Karr M, et al. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005. Clin Infect Dis. 2008;46(11):1637-1646.
12. Al-Rawahi GN, Reynolds S, Porter SD, et al. Community-associated CMRSA-10 (USA-300) is the predominant strain among methicillin-resistant Staphylococcus aureus strains causing skin and soft tissue infections in patients presenting to the emergency department of a Canadian tertiary care hospital. J Emerg Med. 2010;38(1):6-11.
13. Gonzalez BE, Rueda AM, Shelburne SA, Musher DM, Hamill RJ, Hulten KG. Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol. 2006;27(10):1051-1056.
14. Hultén KG, Kaplan SL, Lamberth LB, et al. Hospital-acquired Staphylococcus aureus infections at Texas Children's Hospital, 2001-2007. Infect Control Hosp Epidemiol. 2010;31(2):183-190.
15. Pasquale TR, Jabrocki B, Salstrom SJ, et al; IMPACT-HAP Study Group. Emergence of methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of late-onset nosocomial pneumonia in intensive care patients in the USA. Int J Infect Dis. 2013;17(6): e398-e403.
16. McCaskill ML, Mason EO, Kaplan SL, Hammerman W, Lamberth LB, Hultén KG. Increase of the USA300 clone among community-acquired methicillin-susceptible Staphylococcus aureus causing invasive infections. Pediatr Infect Dis J. 2007;26(12):1122-1127.
17. Kaplan SL, Hulten KG, Mason EO. Staphylococcus aureus infections (coagulase-positive staphylococci). In: Cherry JD, Demmler-Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ, editors. Textbook of Pediatric Infectious Diseases. Philadelphia, PA: Elsevier; 2013;1: 1113-1130.
18. Foster TJ, Geoghegan JA, Ganesh VK, Höök M. Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus. Nat Rev Microbiol. 2014;12(1):49-62.
19. Hair PS, Ward MD, Semmes OJ, Foster TJ, Cunnion KM. Staphylococcus aureus clumping factor A binds to complement regulator factor I and increases factor I cleavage of C3b. J Infect Dis. 2008;198(1):125-133.
20. Hair PS, Echague CG, Sholl AM, et al. Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis. Infect Immun. 2010;78(4):1717-1727.
21. Sharp JA, Echague CG, Hair PS, et al. Staphylococcus aureus surface protein SdrE binds complement regulator factor H as an immune evasion tactic. PLoS One. 2012;7(5):e38407.
22. Panton PN, Valentine FCO. Staphylococcal toxins. Lancet. 1932;219(5662):506-508.
23. Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest. 2007;87(1):3-9.
24. Bocchini CE, Hulten KG, Mason EO, Gonzalez BE, Hammerman WA, Kaplan SL. Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children. Pediatrics. 2006;117(2):433-440.
25. Gordon RJ, Chez N, Jia H, et al. The NOSE study (nasal ointment for Staphylococcus aureus eradication): a randomized controlled trial of monthly mupirocin in HIV-infected individuals. J Acquir Immune Defic Syndr. 2010;55(4):466-472.
26. Senthilkumar A, Kumar S, Sheagren JN. Increased incidence of Staphylococcus aureus bacteremia in hospitalized patients with acquired immunodeficiency syndrome. Clin Infect Dis. 2001;33(8): 1412-1416.
27. Diep BA, Chambers HF, Graber CJ, et al. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med. 2008;148(4):249-257.
28. Diep BA, Gill SR, Chang RF, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant Staphylococcus aureus. Lancet. 2006;367(9512):731-739.
29. McNeil JC, Hulten KG, Kaplan SL, Schwarzwald HL, Mason EO. Staphylococcus aureus infections in HIV-positive children and adolescents. Pediatr Infect Dis J. 2012;31(3):284-286.
30. Lee NE, Taylor MM, Bancroft E, et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis. 2005;40(10):1529-1534.
31. Siberry GK, Frederick T, Emmanuel P, et al. Methicillin-resistant Staphylococcus aureus infections in human immunodeficiency virus-infected children and adolescents. AIDS Res Treat. 2012;2012: 627974.
32. Cotton MF, Wasserman E, Smit J, Whitelaw A, Zar HJ. High incidence of antimicrobial resistant organisms including extended spectrum beta-lactamase producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus in nasopharyngeal and blood isolates of HIV-infected children from Cape Town, South Africa. BMC Infect Dis. 2008;8:40.
33. Groome MJ, Albrich WC, Wadula J, Khoosal M, Madhi SA. Community-onset Staphylococcus aureus bacteraemia in hospitalised African children: high incidence in HIV-infected children and high prevalence of multidrug resistance. Paediatr Int Child Health. 2012;32(3):140-146.
34. Zar HJ, Hanslo D, Hussey G. The impact of HIV infection and trimethoprim-sulphamethoxazole prophylaxis on bacterial isolates from children with community-acquired pneumonia in South Africa. J Trop Pediatr. 2003;49(2):78-83.
35. Wood SM, Shah SS, Bafana M, et al. Epidemiology of methicillin-resistant Staphylococcus aureus bacteremia in Gaborone, Botswana. Infect Control Hosp Epidemiol. 2009;30(8):782-785.
36. Favre D, Lederer S, Kanwar B, et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. 2009;5(2):e1000295.
37. Cho JS, Pietras EM, Garcia NC, et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest. 2010;120(5):1762-1773.
38. Maher BM, Mulcahy ME, Murphy AG, et al. Nlrp-3-driven interleukin 17 production by γδT cells controls infection outcomes during Staphylococcus aureus surgical site infection. Infect Immun. 2013;81(12):4478-4489.
39. Archer NK, Harro JM, Shirtliff ME. Clearance of Staphylococcus aureus nasal carriage is T cell dependent and mediated through interleukin-17A expression and neutrophil influx. Infect Immun. 2013;81(6): 2070-2075.
40. Buchacz K, Patel P, Taylor M, et al. Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections. AIDS. 2004;18(15):2075-2079.
41. aidsinfo.nih.gov [homepage on the Internet]. Guidelines for the prevention and treatment of opportunistic infections In HIV-exposed and HIV-infected Children; 2013. AidsInfo. US Department of Human Health and Services. Available from: http://aidsinfo.nih.gov/guidelines. Accessed March 12, 2014.
42. Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30(Suppl 1): S51-S59.
43. Gopal AK, Fowler VG Jr, Shah M, et al. Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy. J Clin Oncol. 2000;18(5):1110-1115.
44. Kang CI, Song JH, Chung DR, et al; Korean Network for Study on Infectious Diseases (KONSID). Bloodstream infections in adult patients with cancer: clinical features and pathogenic significance of Staphylococcus aureus bacteremia. Support Care Cancer. 2012;20(10): 2371-2378.
45. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001;344(1):11-16.
46. Hagiwara S, Miwa A, Yoshida M, et al. Methicillin-resistant Staphylococcus aureus: colonization and development of infection in patients with haematological disorders. Eur J Haematol. 1995;55(4): 267-271.
47. Ghanem HM, Abou-Alia AM, Alsirafy SA. Prevalence of methicillin-resistant Staphylococcus aureus colonization and infection in hospitalized palliative care patients with cancer. Am J Hosp Palliat Care. 2013;30(4):377-379.
48. Srinivasan A, Seifried SE, Zhu L, et al. Increasing prevalence of nasal and rectal colonization with methicillin-resistant Staphylococcus aureus in children with cancer. Pediatr Blood Cancer. 2010;55(7):1317-1322.
49. McCullers JA, Williams BF, Wu S, et al. Healthcare-Associated Infections at a Children's Cancer Hospital, 1983-2008. J Pediatric Infect Dis Soc. 2012;1(1):26-34.
50. Bakhshi S, Padmanjali KS, Arya LS. Infections in childhood acute lymphoblastic leukemia: an analysis of 222 febrile neutropenic episodes. Pediatr Hematol Oncol. 2008;25(5):385-392.
51. Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis. 2007;45(10):1296-1304.
52. Santolaya ME, Alvarez AM, Avilés CL, et al. Admission clinical and laboratory factors associated with death in children with cancer during a febrile neutropenic episode. Pediatr Infect Dis J. 2007;26(9): 794-798.
53. McNeil JC, Hulten KG, Kaplan SL, Mahoney DH, Mason EO. Staphylococcus aureus infections in pediatric oncology patients: high rates of antimicrobial resistance, antiseptic tolerance and complications. Pediatr Infect Dis J. 2013;32(2):124-128.
54. Srinivasan A, Seifried S, Zhu L, et al. Staphylococcus aureus bacteremia in pediatric patients with cancer. Pediatr Infect Dis J. 2010;29(2):172-174.
55. Srinivasan A, Seifried S, Zhu L, et al. Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus infections in children with cancer. Pediatr Blood Cancer. 2009;53(7):1216-1220.
56. Talan DA, Krishnadasan A, Gorwitz RJ, et al; EMERGEncy ID Net Study Group. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis. 2011;53(2):144-149.
57. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1-45.
58. Ferretti GA, Hansen IA, Whittenburg K, Brown AT, Lillich TT, Ash RC. Therapeutic use of chlorhexidine in bone marrow transplant patients: case studies. Oral Surg Oral Med Oral Pathol. 1987;63(6):683-687.
59. DeRiso AJ 2nd, Ladowski JS, Dillon TA, Justice JW, Peterson AC. Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery. Chest. 1996;109(6): 1556-1561.
60. Bleasdale SC, Trick WE, Gonzalez IM, Lyles RD, Hayden MK, Weinstein RA. Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med. 2007;167(19):2073-2079.
61. Kassakian SZ, Mermel LA, Jefferson JA, Parenteau SL, Machan JT. Impact of chlorhexidine bathing on hospital-acquired infections among general medical patients. Infect Control Hosp Epidemiol. 2011;32(3): 238-243.
62. Miller MR, Niedner MF, Huskins WC, et al; National Association of Children's Hospitals and Related Institutions Pediatric Intensive Care Unit Central Line-Associated Bloodstream Infection Quality Transformation Teams. Reducing PICU central line-associated bloodstream infections: 3-year results. Pediatrics. 2011;128(5):e1077-e1083.
63. Pereira Pinto L, de Souza LB, Gordón-Núñez MA, et al. Prevention of oral lesions in children with acute lymphoblastic leukemia. Int J Pediatr Otorhinolaryngol. 2006;70(11):1847-1851.
64. Popovich KJ, Hota B, Hayes R, Weinstein RA, Hayden MK. Effectiveness of routine patient cleansing with chlorhexidine gluconate for infection prevention in the medical intensive care unit. Infect Control Hosp Epidemiol. 2009;30(10):959-963.
65. Grinius LL, Goldberg EB. Bacterial multidrug resistance is due to a single membrane protein which functions as a drug pump. J Biol Chem. 1994;269(47):29998-30004.
66. Rouch DA, Cram DS, DiBerardino D, Littlejohn TG, Skurray RA. Efflux-mediated antiseptic resistance gene qacA from Staphylococcus aureus: common ancestry with tetracycline- and sugar-transport proteins. Mol Microbiol. 1990;4(12):2051-2062.
67. Smith K, Gemmell CG, Hunter IS. The association between biocide tolerance and the presence or absence of qac genes among hospital-acquired and community-acquired MRSA isolates. J Antimicrob Chemother. 2008;61(1):78-84.
68. Truong-Bolduc QC, Villet RA, Estabrooks ZA, Hooper DC. Native efflux pumps contribute resistance to antimicrobials of skin and the ability of Staphylococcus aureus to colonize skin. J Infect Dis. Epub December 23, 2013.
69. Laupland KB, Ross T, Gregson DB. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. J Infect Dis. 2008;198(3): 336-343.
70. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Pediatrics. 1999; 103(4):e39.
71. Florescu DF, McCartney AM, Qiu F, et al. Staphylococcus aureus infections after liver transplantation. Infection. 2012;40(3):263-269.
72. Nafady-Hego H, Elgendy H, Moghazy WE, Fukuda K, Uemoto S. Pattern of bacterial and fungal infections in the first 3 months after pediatric living donor liver transplantation: an 11-year single-center experience. Liver Transpl. 2011;17(8):976-984.
73. Desai D, Desai N, Nightingale P, Elliott T, Neuberger J. Carriage of methicillin-resistant Staphylococcus aureus is associated with an increased risk of infection after liver transplantation. Liver Transpl. 2003;9(7):754-759.
74. Shields RK, Clancy CJ, Minces LR, et al. Staphylococcus aureus infections in the early period after lung transplantation: epidemiology, risk factors, and outcomes. J Heart Lung Transplant. 2012;31(11): 1199-1206.
75. Oliveira-Cunha M, Bowman V, di Benedetto G, et al. Outcomes of methicillin-resistant Staphylococcus aureus infection after kidney and/or pancreas transplantation. Transplant Proc. 2013;45(6):2207-2210.
76. Singh N, Squier C, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV. Impact of an aggressive infection control strategy on endemic Staphylococcus aureus infection in liver transplant recipients. Infect Control Hosp Epidemiol. 2006;27(2):122-126.
77. Bocchini CE, Mason EO, Hulten KG, Hammerman WA, Kaplan SL. Recurrent community-associated Staphylococcus aureus infections in children presenting to Texas Children's Hospital in Houston, Texas. Pediatr Infect Dis J. 2013;32(11):1189-1193.
78. Fritz SA, Hogan PG, Hayek G, et al. Household versus individual approaches to eradication of community-associated Staphylococcus aureus in children: a randomized trial. Clin Infect Dis. 2012;54(6): 743-751.
79. Wolach B, Gavrieli R, Roos D, Berger-Achituv S. Lessons learned from phagocytic function studies in a large cohort of patients with recurrent infections. J Clin Immunol. 2012;32(3):454-466.
80. van den Berg JM, Kuijpers TW. Educational paper: Defects in number and function of neutrophilic granulocytes causing primary immunodeficiency. Eur J Pediatr. 2011;170(11):1369-1376.
81. Song E, Jaishankar GB, Saleh H, Jithpratuck W, Sahni R, Krishnaswamy G. Chronic granulomatous disease: a review of the infectious and inflammatory complications. Clin Mol Allergy. 2011; 9(1):10.
82. Mouy R, Fischer A, Vilmer E, Seger R, Griscelli C. Incidence, severity, and prevention of infections in chronic granulomatous disease. J Pediatr. 1989;114(4 Pt 1):555-560.
83. van den Berg JM, van Koppen E, Ahlin A, et al. Chronic granulomatous disease: the European experience. PLoS One. 2009;4(4):e5234.
84. Margolis DM, Melnick DA, Alling DW, Gallin JI. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis. 1990;162(3):723-726.
85. Gallin JI, Alling DW, Malech HL, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med. 2003;348(24):2416-2422.
86. Leung T, Chik K, Li C, Shing M, Yuen P. Bone marrow transplantation for chronic granulomatous disease: long-term follow-up and review of literature. Bone Marrow Transplant. 1999;24(5):567-570.
87. Chinen J, Shearer WT. Primary immunodeficiency. In: Cherry JD, Demmler-Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ, editors. Textbook of Pediatric Infectious Diseases. Vol 1. Philadelphia, PA: Elsevier; 2014:903-920.
88. Grimbacher B, Holland SM, Puck JM. Hyper-IgE syndromes. Immunol Rev. 2005;203:244-250.
89. Mogensen TH. STAT3 and the Hyper-IgE syndrome: Clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties. JAKSTAT. 2013;2(2):e23435.
90. Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008;452(7188):773-776.
91. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92(1):34-48.
92. Schweizer ML, Furuno JP, Harris AD, et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis. 2011;11:279.
93. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285-292.
94. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56-e93.
95. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82-98.
96. Gordon CL, Thompson C, Carapetis JR, Turnidge J, Kilburn C, Currie BJ. Trough concentrations of vancomycin: adult therapeutic targets are not appropriate for children. Pediatr Infect Dis J. 2012; 31(12):1269-1271.
97. Herigon JC, Hersh AL, Gerber JS, Zaoutis TE, Newland JG. Antibiotic management of Staphylococcus aureus infections in US children's hospitals, 1999-2008. Pediatrics. 2010;125(6):e1294-e1300.
98. Martinez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J. 2003;22(7): 593-598.
99. Hyun DY, Mason EO, Forbes A, Kaplan SL. Trimethoprim-sulfamethoxazole or clindamycin for treatment of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J. 2009;28(1):57-59.
100. Williams DJ, Cooper WO, Kaltenbach LA, et al. Comparative effectiveness of antibiotic treatment strategies for pediatric skin and soft-tissue infections. Pediatrics. 2011;128(3):e479-e487.
101. Jantausch BA, Deville J, Adler S, et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatr Infect Dis J. 2003;22(Suppl 9):S164-S171.
102. Moschovi M, Trimis G, Tsotra M, et al. Efficacy and safety of linezolid in immunocompromised children with cancer. Pediatr Int. 2010; 52(5):694-698.
103. Ardura MI, Mejías A, Katz KS, Revell P, McCracken GH Jr, Sánchez PJ. Daptomycin therapy for invasive Gram-positive bacterial infections in children. Pediatr Infect Dis J. 2007;26(12):1128-1132.
104. Palma DM, Giordano S, Neville Cracchiolo A, Zangara V, Coffaro G, Tetamo R. Daptomycin in the treatment of invasive Gram-positive bacterial infections in children: personal experience. Minerva Pediatr. 2013;65(2):173-178.
105. File TM, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010;51(12):1395-1405.
106. Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T; CANVAS 1 investigators. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl 4):iv41-iv51.
107. Manuel O, Lien D, Weinkauf J, Humar A, Cobos I, Kumar D. Methicillin-resistant Staphylococcus aureus infection after lung transplantation: 5-year review of clinical and molecular epidemiology. J Heart Lung Transplant. 2009;28(11):1231-1236.
108. Gupta MR, Valentine VG, Walker JE Jr, et al. Clinical spectrum of gram-positive infections in lung transplantation. Transpl Infect Dis. 2009;11(5):424-431.
109. Bouchut JC, Stamm D, Boillot O, Lepape A, Floret D. Postoperative infectious complications in paediatric liver transplantation: a study of 48 transplants. Paediatr Anaesth. 2001;11(1):93-98.
110. George DL, Arnow PM, Fox AS, et al. Bacterial infection as a complication of liver transplantation: epidemiology and risk factors. Rev Infect Dis. 1991;13(3):387-396.
111. Chen M, Kallenberg CG. ANCA-associated vasculitides - advances in pathogenesis and treatment. Nat Rev Rheumatol. 2010;6(11): 653-664.